α-Synuclein and tau, two targets for dementia

Matías Silva, Valentina Caro, Camila Guzmán, George Perry, Carlos Areche, Alberto Cornejo

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Citation (Scopus)

Abstract

Older people are increasing in number worldwide and they are affected by neurodegenerative disorders. Tauopathies are neurodegenerative disorders that involve diseases such as progressive supranuclear palsy (PSP), frontotemporal dementia linked to chromosome 17 (FTD-17), corticobasal degeneration, and Alzheimer's disease (AD) among others. Other neurodegenerative disorders such as Parkinson's disease is characterized for inclusion denominated as Lewis bodies conformed by hyperphosphorylated alpha-synuclein protein (α-syn). However, there are some neurodegenerative disorders that overlap each other such as dementia with Lewy bodies (DLB), Lewy body variant of AD and Parkinson's disease with dementia (PDD). Moreover, there is an increase in the number of patients of PD with dementia and patients with AD with Lewy body's inclusions in post mortem samples. Thus, we find pertinent to discuss both covalent and noncovalent inhibitors targeting alpha-synuclein and tau.

Original languageEnglish
Title of host publicationStudies in Natural Products Chemistry
PublisherElsevier Science B.V.
Pages1-25
Number of pages25
DOIs
Publication statusPublished - 2021

Publication series

NameStudies in Natural Products Chemistry
Volume67
ISSN (Print)1572-5995

Keywords

  • Covalent and noncovalent interactions
  • Dementia
  • Natural compounds
  • Neurodegenerative disorders
  • Oligomers

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'α-Synuclein and tau, two targets for dementia'. Together they form a unique fingerprint.

Cite this